At least in a population of Southern Chinese adults, a high risk of fatty liver disease is independently associated with an increased count of red blood cells, a new study reports.
There is a significant correlation between the exposure to heavy metals in the soil and fatty liver disease in a population of lean Taiwanese men, a new study reveals.
Patients with chronic liver diseases such as hepatitis and cirrhosis are at a higher risk of colorectal cancer (CRC) even after liver transplantation.
Optimal retreatment of patients with hepatitis C depends on differentiating virologic relapse from reinfection
Patients with detectable HCV RNA following sustained virologic response 12 weeks after the end of treatment should be investigated to determine if they have virologic relapse or reinfection.
EGFR-ASAP1 signalling may contribute to hepatoblastoma (HBL) tumorigenesis and invasiveness, say US-based researchers.
Serum osteoprotegrin levels may eventually be used as a reliable marker for bone loss and osteoporosis risk, at least in women with chronic kidney disease (CKD), a new study reports.
Once-daily daclatasvir therapy for 12 weeks plus sofosbuvir is effective in the treatment of chronic hepatitis C, as shown in a review.
A study suggests that patients with metabolic syndrome (MS) associated with hyperferritinemia (HF), or what is known as dysmetabolic hyperferritinemia (DH), may have normal liver iron concentration (LIC) values.
Combination therapy with daclatasvir and asunaprevir may be safe and effective in patients with chronic genotype 1 hepatitis C virus (HCV) infection and compensated liver cirrhosis, according to a study.
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination attains high SVR 12 rates in HCV-infected patients
Fixed-dose combination of daclatasvir, asunaprevir, and beclabuvir resulted in high rates of sustained virologic response at post-treatment week 12 (SVR12) in Japanese patients infected with HCV genotype 1, as stated in a phase III study.